IRCT20121216011763N46 IRCT 2020-05-04 Esfahan University of Medical Sciences Effect of curcumin-piperine in patients with coronavirus (COVID-19) Effect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus (COVID-19): A randomized, double-blind, placebo-controlled clinical trial study 2020-05-04 anticipated 100 Complete https://irct.ir/trial/47529 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomly, based on the permuted block randomization method, using blocks of 4 that will be blocked based on gender variables and will be assigned to one of two curcumin-piperine and placebo groups. The enrolling participants, and assigning participants to the groups will be carried out by a trained nutritionist. Researchers will not be informed about the randomization process until the completion of data analyses, Blinding description: This study is a double-blind clinical trial (participant, researcher). The curcumin-piperine supplement and its placebo will be packaged in similar boxes, and the researcher and patients will not be informed of the contents of the packs until the end of the study. N/A coronavirus (covid-19) disease. Intervention 1: Intervention group: Two curcumin-piperine capsules (500 mg of curcumin + 5 mg of piperine) will be given daily for 2 weeks after lunch and dinner. Intervention 2: Control group: 2 placebo capsules ( containing 505 mg of maltodextrin) will be given daily after lunch and dinner for 2 weeks. Yes - There is a plan to make this available What will be shared: The collected deidentified for the primary outcome measure only will be shared. When: 12 months after publication To whom: Available for people working in academic institutions Conditions: To conduct similar studies Where to obtain: askari@mui.ac.ir How to obtain: The data will send as soon as possible, after receiving the request. Comments: